Floatz logo

pds01adc

Adrenal Gland Cancer

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Adrenal Gland Cancer cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2CCC
Floxuridine
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 1/2CCC
FAPi-46
Jonsson Comprehensive Cancer Center
Phase 1CC
FLUDEOXYGLUCOSE
Jonsson Comprehensive Cancer Center
Phase 1CC
Fpac
National Cancer Institute (NCI)
Early Phase 1C
BMS-986218
M.D. Anderson Cancer Center
Phase 1/2D

Same molecule, other indications

pds01adc is also rated in:

prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →
intrahepatic bile duct cancerDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →